October 3, 2023 06:43 AM EDTUpdated October 4, 04:08 AM
FDA+
Manufacturing

FDA re­jects Gal­der­ma’s liq­uid neu­ro­tox­in due to CMC is­sues 

Anna Brown

News Reporter

Gal­der­ma’s neu­ro­tox­in for frown lines and crow’s feet was re­ject­ed by the FDA on Mon­day af­ter find­ing is­sues with its chem­istry …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

In sur­prise, study sug­gests Covid mR­NA vac­cines may boost can­cer im­munother­a­py ef­fi­ca­cy

Pfiz­er tees up Phase 3 test in weight man­age­ment — but in an un­ex­pect­ed area

Ex-Kite lead­ers step in at Kyver­na as CEO ex­its af­ter land­ing year's sec­ond-biggest IPO

BioN­Tech rolls out Phase 2 lung can­cer da­ta as VEGF bis­pecifics take cen­ter stage

Im­mat­ics los­es Bris­tol My­er­s' sup­port on Phase 1 bis­pe­cif­ic T cell en­gager

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times